Trevi Therapeutics Presents New Findings on Cough Relief in PH2A Canal Trial at CHEST 2024
A New Breakthrough in Cough Relief: Analysis of Nalbuphine ER Treatment in Idiopathic Pulmonary Fibrosis Patients Introduction Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER. Trevi Therapeutics, Inc. has announced that data from the Phase 2a CANAL trial will be presented…